Diabetes Mellitus Type 2 and Non-alcoholic Fatty Liver Disease. The Effects of Metformin
Journal Title: Міжнародний ендокринологічний журнал - Year 2013, Vol 5, Issue 53
Abstract
Diabetes mellitus (DM) type 2 in clinical practice is often associated with non-alcoholic fatty liver disease (NAFLD), which has a number of clinical and morphological forms and develops in patients who do not abuse alcohol. The combination of DM type 2 and NAFLD is associated not only with a high risk of developing liver cirrhosis and hepatocellular carcinoma in these patients. Although all aspects of the etiology of NAFLD is not fully known, it is points to the role of insulin resistance in its development. This concept has facilitated a number of clinical studies using metformin as the insulin sensitizer in insulin-resistant patients with NAFLD. The findings emphasize the importance of metformin in the treatment of NAFLD in combination with a hypocaloric diet and the control of body weight. It is also reported about other tissue effects of metformin in NAFLD.
Authors and Affiliations
V. I. Pankiv
Keywords
Related Articles
- EP ID EP233134
- DOI -
- Views 42
- Downloads 0
Assessment of Efficacy of NPH Insulin in Cartridges Injection Technique
No abstract
Effect of Guarem on the Body Weight and Basic Indices of Lipid and Carbohydrate Metabolism in Overweight or Obese Patients
The article presents research findings of the Guarem effects on body weight, the basic indices of carbohydrate and lipid metabolism. Materials and Methods. We observed 40 patients divided into 3 groups. The first group (...
Epidemiology and Morphological Features of Thyroid Cancer in People Living in Vinnytsia Region
Background. Thyroid cancer (TC) is the most common tumor of the endocrine glands. The problem of thyroid cancer in Ukraine went far beyond the consequences of the Chernobyl disaster and is characterized by increasing mor...
Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation Part 1. Pharmacokinetic and Pharmacodynamic Aspects
This review, consisting of two parts, considers a new formulation of insulin glargine (rDNA origin) in the form of injections 300 U/ml (Gla-300, Toujeo®). Gla-300 is a next generation basal insulin with a novel formulati...
Hyperparathyroidism: Diagnosis, Clinical Signs and Symptoms, Modern Approaches to Treatment
.